Compass Therapeutics, Inc.
CMPXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCompass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. With a market capitalization of $385.4M, it sits in small-cap territory. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Market Cap
$385.4M
Beta
0.75
P/E (TTM)
—
P/E (Fwd)
-4.63
EPS (TTM)
$-0.39
EPS (Fwd)
$-0.46
ROE
-46.0%
ROA
-27.9%
Cash
$194.7M
Total Debt
$9.8M
Free CF
-$30.0M
52W Change
-31.6%
Annual Financials
Cash vs Debt
Compass Therapeutics, Inc. holds $194.7M in cash against $9.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$30.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -46.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CMPX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.